Nurix Therapeutics Swings to $549.8M Q3 Profit on Roche License Revenue
Nurix Therapeutics, Inc. (NRIX) reported a significant financial turnaround for the third quarter of 2026, generating $673.1 million in revenue compared to $7.9 million in the same period last year. Net income reached $549.8 million, or $4.73 per diluted share, swinging from a net loss of $86.4 million, or $1.03 per share, a year earlier.
The quarter's dramatic jump in revenue was primarily driven by the recognition of $653.2 million in license revenue from partner Roche. The influx of capital shifts the company's revenue mix heavily toward collaboration fees. Nurix has received $1.2 billion in total payments to date across its major pharmaceutical partnerships, which include Roche, Gilead, Sanofi, and Pfizer, with potential milestone and royalty payments reaching up to $7.2 billion.
Looking ahead, Nurix is reallocating resources by stopping development on zelebrudomide to focus on key clinical programs. The company has advanced bexobrutideg into a global Phase 3 trial and dosed the first patient in Phase 1b expansion studies for NX-1607. Operating costs in research, development, and administration are rising to support late-stage clinical trials and manufacturing scaling, with costs shared under its agreement with Roche.
Key points
- Nurix Therapeutics posted Q3 2026 revenue of $673.1 million, up from $7.9 million in the year-ago quarter.
- Net income reached $549.8 million, or $4.73 per diluted share, swinging from an $86.4 million loss a year earlier.
- Performance was powered by recognizing $653.2 million in license revenue from collaboration partner Roche.
- Clinical focus shifts to bexobrutideg Phase 3 trials and NX-1607 while development of zelebrudomide was ended.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What were Nurix Therapeutics' Q3 2026 earnings results?
Nurix Therapeutics reported Q3 2026 net income of $549.8 million, or $4.73 per diluted share, on total revenue of $673.1 million.
Why did Nurix Therapeutics revenue increase significantly in Q3 2026?
The revenue growth was primarily driven by recognizing $653.2 million in license revenue under its collaboration agreement with Roche.
Which clinical programs is Nurix Therapeutics prioritizing?
Nurix is advancing bexobrutideg into global Phase 3 trials and expanding Phase 1b studies for NX-1607, while discontinuing development of zelebrudomide.